Literature DB >> 7910372

Kinetic evidence suggesting that the multidrug transporter differentially handles influx and efflux of its substrates.

W D Stein1, C Cardarelli, I Pastan, M M Gottesman.   

Abstract

A kinetic approach was used to analyze the mechanism by which a substitution of valine for glycine at position 185 in the multidrug transporter alters its substrate specificity so that colchicine and etoposide transport is increased, daunorubicin transport is unchanged, and vinblastine transport is decreased. Time courses for uptake and efflux of colchicine, vinblastine, etoposide, and daunorubicin for NIH/3T3 mouse cells transfected with wild-type (MDR1-G185) and mutant (MDR1-V185) strains of the human mdr1 gene were determined at room temperature in the presence and absence of an energy supply. The initial rate of vinblastine uptake was reduced approximately 5-fold by glucose feeding of ATP-depleted wild-type (MDR1-G185) cells but was only halved in MDR1-V185 transfectants. In contrast, glucose feeding decreased the initial rate of colchicine uptake approximately 4-fold in the MDR1-V185 (mutant) transfectant but not in the MDR1-G185 (wild-type) transfectant. Efflux of colchicine was accelerated > 5-fold in both the MDR1-V185 (mutant) and MDR1-G185 (wild-type) transfectants when glucose was given to raise ATP levels. The effects on initial rates of colchicine uptake accounted semiquantitatively for the increased colchicine resistance of MDR1-V185 (mutant) transfectants. Similar effects were found for etoposide in the MDR-V185 transfectants. Quinidine in the external medium greatly inhibited drug entry rates but had little effect on efflux, whereas verapamil inhibited both uptake and efflux. A possible interpretation of these data is that the multidrug transporter extracts drugs from the external and internal halves of the membrane bilayer by different paths, which are distinguishable by mutation and inhibitors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7910372

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  23 in total

1.  Stereoselective transport of hydrophilic quaternary drugs by human MDR1 and rat Mdr1b P-glycoproteins.

Authors:  Guido J E J Hooiveld; Janette Heegsma; Jessica E van Montfoort; Peter L M Jansen; Dirk K F Meijer; Michael Müller
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

Review 2.  P glycoprotein in human immunodeficiency virus type 1 infection and therapy.

Authors:  Sanjay U C Sankatsing; Jos H Beijnen; Alfred H Schinkel; Joep M A Lange; Jan M Prins
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

3.  Pharmacokinetic consequences of active drug efflux at the blood-brain barrier.

Authors:  Stina Syvänen; Rujia Xie; Selma Sahin; Margareta Hammarlund-Udenaes
Journal:  Pharm Res       Date:  2006-04-07       Impact factor: 4.200

4.  Intestinal absorption barriers and transport mechanisms, including secretory transport, for a cyclic peptide, fibrinogen antagonist.

Authors:  B J Aungst; H Saitoh
Journal:  Pharm Res       Date:  1996-01       Impact factor: 4.200

5.  Influence of passive permeability on apparent P-glycoprotein kinetics.

Authors:  K A Lentz; J W Polli; S A Wring; J E Humphreys; J E Polli
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

6.  Screening of multidrug-resistance sensitive drugs by in situ brain perfusion in P-glycoprotein-deficient mice.

Authors:  S Cisternino; C Rousselle; C Dagenais; J M Scherrmann
Journal:  Pharm Res       Date:  2001-02       Impact factor: 4.200

7.  Repacking of the transmembrane domains of P-glycoprotein during the transport ATPase cycle.

Authors:  M F Rosenberg; G Velarde; R C Ford; C Martin; G Berridge; I D Kerr; R Callaghan; A Schmidlin; C Wooding; K J Linton; C F Higgins
Journal:  EMBO J       Date:  2001-10-15       Impact factor: 11.598

8.  Functional characterization of a glycine 185-to-valine substitution in human P-glycoprotein by using a vaccinia-based transient expression system.

Authors:  M Ramachandra; S V Ambudkar; M M Gottesman; I Pastan; C A Hrycyna
Journal:  Mol Biol Cell       Date:  1996-10       Impact factor: 4.138

9.  Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa?

Authors:  Fuxing Tang; Kazutoshi Horie; Ronald T Borchardt
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

Review 10.  P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells.

Authors:  T Licht; I Pastan; M Gottesman; F Herrmann
Journal:  Ann Hematol       Date:  1994-10       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.